Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Staphylococcus Aureus Network Adaptive Platform Trial

Staphylococcus Aureus Network Adaptive Platform Trial

Medical Conditions

Staphylococcal Infections
Bacteremia


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Feb 2022 Dec 2028

Publications

"Tong SYC, Mora J, Bowen AC, Cheng MP, Daneman N, Goodman AL, Heriot GS, Lee TC, Lewis RJ, Lye DC, Mahar RK, Marsh J, McGlothlin A, McQuilten Z, Morpeth SC, Paterson DL, Price DJ, Roberts JA, Robinson JO, van Hal SJ, Walls G, Webb SA, Whiteway L, Yahav D, Davis JS; Staphylococcus aureus Network Adaptive Platform (SNAP) Study Group. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. Clin Infect Dis. 2022 Nov 30;75(11):2027-2034. doi: 10.1093/cid/ciac476. Erratum In: Clin Infect Dis. 2023 Apr 17;76(8):1532-1533. doi: 10.1093/cid/ciac730."; "35717634"; "Symons TJ, Straiton N, Gagnon R, Littleford R, Campbell AJ, Bowen AC, Stewart AG, Tong SYC, Davis JS. Consumer perspectives on simplified, layered consent for a low risk, but complex pragmatic trial. Trials. 2022 Dec 28;23(1):1055. doi: 10.1186/s13063-022-07023-z."; "36578070"; "Malhame I, Hardy E, Cheng MP, Tong SY, Bowen AC. Walking the walk to include pregnant participants in non-obstetric clinical trials: Insights from the SNAP Trial. Obstet Med. 2023 Mar;16(1):3-4. doi: 10.1177/1753495X231163351. Epub 2023 Mar 22. No abstract available."; "37139509"; "Henderson A, Cheng MP, Chew KL, Coombs GW, Davis JS, Grant JM, Gregson D, Giulieri SG, Howden BP, Lee TC, Nguyen V, Mora JM, Morpeth SC, Robinson JO, Tong SYC, Van Hal SJ; Microbiology Working Group of the Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group. A multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus. J Antimicrob Chemother. 2023 Jun 1;78(6):1499-1504. doi: 10.1093/jac/dkad116."; "37071589"; "de Kretser D, Mora J, Bloomfield M, Campbell A, Cheng MP, Guy S, Hensgens M, Kalimuddin S, Lee TC, Legg A, Mahar RK, Marks M, Marsh J, McGlothlin A, Morpeth SC, Sud A, Ten Oever J, Yahav D, Tong SY, Davis JS, Walls G, Goodman AL, Bonten M; Staphylococcus aureus Network Adaptive Platform (SNAP) Study Group members. Early oral antibiotic switch in Staphylococcus aureus bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol. Clin Infect Dis. 2023 Oct 31:ciad666. doi: 10.1093/cid/ciad666. Online ahead of print."; "37921609"; "Mahar RK, McGlothlin A, Dymock M, Lee TC, Lewis RJ, Lumley T, Mora J, Price DJ, Saville BR, Snelling T, Turner R, Webb SA, Davis JS, Tong SYC, Marsh JA; SNAP Global Trial Steering Committee. A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial. Trials. 2023 Dec 6;24(1):795. doi: 10.1186/s13063-023-07718-x."; "38057927"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Cefazolin

Intervention Arm Group : Methicillin-resistant staphylococcus aureus (MRSA) - Standard + B-Lactam Arm (backbone therapy);Methicillin-susceptible staphylococcus aureus (MSSA) - Interventional Arm (backbone therapy);

Intervention Type : DRUG
Intervention Description : benzylpenicillin

Intervention Arm Group : Penicillin-susceptible staphylococcus aureus (PSSA) - Interventional Arm (backbone therapy);

Intervention Type : DRUG
Intervention Description : Clindamycin

Intervention Arm Group : Adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm;

Intervention Type : DRUG
Intervention Description : Vancomycin or Daptomycin

Intervention Arm Group : Methicillin-resistant staphylococcus aureus (MRSA) - Standard + B-Lactam Arm (backbone therapy);

Intervention Type : OTHER
Intervention Description : This involves testing a strategy rather than individual antibiotic agents

Intervention Arm Group : Switch to oral antibiotics at trial day 7 (+/- 2 days) or Day 14 (+/- 2 days) if eligible.;

Intervention Type : RADIATION
Intervention Description : Whole body FDG PET/CT imaging will be performed using a standardised protocol describing patient preparation and minimum specifications for radiopharmaceutical production, quality control, and PET/CT acquisition.

Intervention Arm Group : PET/CT scan at trial day 7 (+/- 2 days) if eligible;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Liverpool University Hospital
    Liverpool
  • Great Ormond Street
    London
  • University Hospital Southampton
    Southampton
  • University College London Hospitals
    London
  • Kings College Hospital
    London
  • Newcastle upon Tyne Hospitals
    Newcastle upon Tyne
  • University Hospitals Bristol and Weston
    Bristol
  • Cambridge University Hospitals
    Cambridge
  • University Hospitals Birmingham
    Birmingham
  • Nottingham University Hospitals
    Nottingham
  • Oxford University Hospitals
    Oxford
  • NHS Grampian
    Aberdeen
  • Imperial College Healthcare
    London
  • Barts Health
    London
  • NHS Tayside
    Dundee
  • Swansea Bay University Health Board
    Swansea
  • Royal Free London
    London
  • NHS Forth Valley
    Stirling
  • Leeds Teaching Hospitals
    Leeds
  • Royal Cornwall Hospitals
    Cornwall
  • Brighton and Sussex University Hospitals
    Brighton
  • Sheffield Teaching Hospitals
    Sheffield
  • Greater Glasgow and Clyde
    Glasgow
  • North Bristol
    Bristol
  • Cardiff and Vale University
    Cardiff
  • Royal Devon University Healthcare
    Devon
  • Lothian Western General
    Edinburgh
  • NHS Golden Jubilee
    Glasgow
  • Hull University Teaching Hospitals
    Hull
  • Guys and St Thomas'
    London
  • Whittington Health
    London
  • Manchester University Hospitals
    Manchester
  • South Tees Hospitals
    South Tees
  • University Hospitals of North Midlands
    Stoke


The study is sponsored by University of Melbourne and is in collaboration with Berry Consultants; McGill University Health Centre/Research Institute of the McGill University Health Centre; Menzies School of Health Research; Aotearoa Clinical Trials; Queensland University of Technology; Sunnybrook Health Sciences Centre; Tan Tock Seng Hospital; Telethon Kids Institute; The Peter Doherty Institute for Infection and Immunity; The University of Queensland; UMC Utrecht; Radboud University Medical Center; King's College London; Rambam Health Care Campus; University College, London; Houston Medical Research Institute.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT05137119
Last updated 03 June 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.